Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

The drug provides both bronchodilation ... could also be heading for approval in COPD – at the second attempt – after reducing exacerbations in the phase 3 MATINEE trial, while Amgen and ...

The problem with COPD is you have obstruction ... improve patients' breathing and decreases the exacerbations. And there are a host of medications we can use now that barely existed or didn ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

Analysts see the drug achieving blockbuster status quickly ... therapy lowered the rate of moderate or severe exacerbations among COPD patients. Amgen and AstraZeneca have hopes for their asthma ...

Asthma–chronic obstructive pulmonary disease (COPD ... trials to evaluate specific drug interventions on important outcomes such as lung function, acute exacerbations, quality of life and ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...